Chart Events
Performance Outlook
| Previous Close | 265.52 |
| Open | 264.74 |
| Bid | 267.26 x 1000 |
| Ask | 267.38 x 800 |
| Day's Range | 263.50 - 268.11 |
| 52 Week Range | 211.71 - 288.46 |
| Volume | |
| Avg. Volume | 2,436,993 |
| Market Cap | 142.871B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 18.97 |
| EPS (TTM) | 14.07 |
| Earnings Date | Jan 29, 2024 - Feb 02, 2024 |
| Forward Dividend & Yield | 8.52 (3.21%) |
| Ex-Dividend Date | Nov 16, 2023 |
| 1y Target Est | 277.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AMGN
Related Research
- Amgen Inc.Weekly Stock ListManagement's ability to "raise guidance" can often be a catalyst for market-beating returns in the quarters ahead. The third-quarter earnings season is wrapping up, with blended earnings (actual results and the consensus for those still to report) showing a 6.3% gain, year-over-year, according to Refinitiv. That is considerably better than the 1.0% expected at the start of the earnings period, and should be enough to end the "earnings recession" that investors have endured over the past three quarters. Propelling the 3Q outperformance were strong gains in Communication Services, up 46%, while Energy again (like last quarter) is performing the worst, down 33%. Our analysts are always on the lookout for companies that boost their outlooks during earnings season. Here is an initial list of BUY-rated companies in Argus Coverage at which management raised guidance or increased its outlook during the 3Q23 EPS reporting season.RatingFair ValueEconomic Moat9 days agoArgus Research
Yahoo FinanceAWS expands big pharma partnerships in manufacturing, AI, and R&D
Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.
BenzingaThis Stock Hasn't Split Since 1999 — $1,000 Invested Then Would Be Worth A Boatload Today
When investing in the stock market, a history of strong returns should be high on your priority list. Combine this with a positive outlook on the future, and you may have a winner to add to your portfolio. Amgen Inc., an American multinational biopharmaceutical company, fits this mold. The company has a 10-year annualized total return of 13.69% through the end of 2022. And if that's not enough to pique your interest, consider this: It pays out billions of dollars in dividends to investors every
ZacksIs Trending Stock Amgen Inc. (AMGN) a Buy Now?
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
